Matthew H Kulke

Matthew H Kulke

UNVERIFIED PROFILE

Are you Matthew H Kulke?   Register this Author

Register author
Matthew H Kulke

Matthew H Kulke

Publications by authors named "Matthew H Kulke"

Are you Matthew H Kulke?   Register this Author

100Publications

3058Reads

44Profile Views

Guidance on Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.

J Nucl Med Technol 2018 Sep 3;46(3):237-244. Epub 2018 Aug 3.

Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnmt.118.209148DOI Listing
September 2018

Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.

J Gastrointest Cancer 2018 Aug 18. Epub 2018 Aug 18.

The West Clinic, 100 N Humphreys Boulevard, Memphis, TN, 38120, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-018-0160-xDOI Listing
August 2018

Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index.

Pancreas 2017 Nov/Dec;46(10):1347-1353

From the *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; †Medical Oncology Department 2, Chinese PLA General Hospital, Beijing, China; ‡Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA; §Collaborative Innovation Center of Tianjin for Medical Epigenetic, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin; ∥College of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China; ¶Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; #Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan, China; **Department of Epidemiology, Harvard T.H. Chan School of Public Health; ††Department of Biostatistics, Harvard T.H. Chan School of Public Health; ‡‡Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School; §§Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; ∥∥Yale Cancer Center; ¶¶Department of Medicine, Yale University School of Medicine; and ##Smilow Cancer Hospital, New Haven, CT.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006676-201711000-0001
Publisher Site
http://dx.doi.org/10.1097/MPA.0000000000000944DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645256PMC
June 2018

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Endocr Relat Cancer 2018 03 12;25(3):309-322. Epub 2018 Jan 12.

Oncology DepartmentHospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-17-0455DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811631PMC
March 2018

Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer.

Authors:
Alison P Klein Brian M Wolpin Harvey A Risch Rachael Z Stolzenberg-Solomon Evelina Mocci Mingfeng Zhang Federico Canzian Erica J Childs Jason W Hoskins Ashley Jermusyk Jun Zhong Fei Chen Demetrius Albanes Gabriella Andreotti Alan A Arslan Ana Babic William R Bamlet Laura Beane-Freeman Sonja I Berndt Amanda Blackford Michael Borges Ayelet Borgida Paige M Bracci Lauren Brais Paul Brennan Hermann Brenner Bas Bueno-de-Mesquita Julie Buring Daniele Campa Gabriele Capurso Giulia Martina Cavestro Kari G Chaffee Charles C Chung Sean Cleary Michelle Cotterchio Frederike Dijk Eric J Duell Lenka Foretova Charles Fuchs Niccola Funel Steven Gallinger J Michael M Gaziano Maria Gazouli Graham G Giles Edward Giovannucci Michael Goggins Gary E Goodman Phyllis J Goodman Thilo Hackert Christopher Haiman Patricia Hartge Manal Hasan Peter Hegyi Kathy J Helzlsouer Joseph Herman Ivana Holcatova Elizabeth A Holly Robert Hoover Rayjean J Hung Eric J Jacobs Krzysztof Jamroziak Vladimir Janout Rudolf Kaaks Kay-Tee Khaw Eric A Klein Manolis Kogevinas Charles Kooperberg Matthew H Kulke Juozas Kupcinskas Robert J Kurtz Daniel Laheru Stefano Landi Rita T Lawlor I-Min Lee Loic LeMarchand Lingeng Lu Núria Malats Andrea Mambrini Satu Mannisto Roger L Milne Beatrice Mohelníková-Duchoňová Rachel E Neale John P Neoptolemos Ann L Oberg Sara H Olson Irene Orlow Claudio Pasquali Alpa V Patel Ulrike Peters Raffaele Pezzilli Miquel Porta Francisco X Real Nathaniel Rothman Ghislaine Scelo Howard D Sesso Gianluca Severi Xiao-Ou Shu Debra Silverman Jill P Smith Pavel Soucek Malin Sund Renata Talar-Wojnarowska Francesca Tavano Mark D Thornquist Geoffrey S Tobias Stephen K Van Den Eeden Yogesh Vashist Kala Visvanathan Pavel Vodicka Jean Wactawski-Wende Zhaoming Wang Nicolas Wentzensen Emily White Herbert Yu Kai Yu Anne Zeleniuch-Jacquotte Wei Zheng Peter Kraft Donghui Li Stephen Chanock Ofure Obazee Gloria M Petersen Laufey T Amundadottir

Nat Commun 2018 02 8;9(1):556. Epub 2018 Feb 8.

Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-02942-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805680PMC
February 2018

Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.

Ann Surg Oncol 2017 Aug 16;24(8):2319-2325. Epub 2017 Mar 16.

Department of Surgery, Division of Surgical Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-017-5839-xDOI Listing
August 2017

Development and Validation of the PREMM Model for Comprehensive Risk Assessment of Lynch Syndrome.

J Clin Oncol 2017 Jul 10;35(19):2165-2172. Epub 2017 May 10.

Fay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.6120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493047PMC
July 2017

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

J Clin Oncol 2017 May 6;35(15):1695-1703. Epub 2017 Apr 6.

James C. Yao and Cesar Moran, MD Anderson Cancer Center, Houston, TX; Katherine A. Guthrie and Shannon McDonough, Fred Hutchinson Cancer Research Center, Seattle, WA; Jonathan R. Strosberg, H. Lee Moffitt Cancer Center, Tampa, FL; Matthew H. Kulke and Jennifer A. Chan, Dana Farber Cancer Institute, Boston, MA; Noelle LoConte, University of Wisconsin, Carbone Cancer Center, Madison, WI; Robert R. McWilliams, Mayo Clinic College of Medicine, Rochester, MN; Edward M. Wolin, University of Kentucky, Lexington, KY; Edward M. Wolin, Montifiore Einstein Cancer Center, New York, NY; Bassam Mattar, Wichita NCORP/Cancer Center of Kansas, Wichita, KS; Helen Chen, NCI Cancer Therapy Evaluation Program, Bethesda, MD; Charles D. Blanke, Oregon Health & Science University, Portland, OR; and Howard S. Hochster, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455764PMC
May 2017

Novel Treatment Options for Neuroendocrine Tumors.

Authors:
Matthew H Kulke

J Natl Compr Canc Netw 2017 05;15(5S):737-739

Presented by Matthew H. Kulke, MD, MMSc, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2017

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

J Clin Oncol 2017 Apr 30;35(10):1086-1095. Epub 2017 Jan 30.

Matthew B. Yurgelun, Matthew H. Kulke, Charles S. Fuchs, Hajime Uno, Chinedu I. Ukaegbu, Lauren K. Brais, Philip G. McNamara, Robert J. Mayer, Deborah Schrag, Jeffrey A. Meyerhardt, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Matthew B. Yurgelun, Matthew H. Kulke, Charles S. Fuchs, Hajime Uno, Jason L. Hornick, Robert J. Mayer, Deborah Schrag, Jeffrey A. Meyerhardt, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Matthew B. Yurgelun, Matthew H. Kulke, Charles S. Fuchs, Jason L. Hornick, Robert J. Mayer, Deborah Schrag, Jeffrey A. Meyerhardt, Kimmie Ng, and Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Brian A. Allen, John Kidd, Nanda Singh, Anne-Renee Hartman, and Richard J. Wenstrup, Myriad Genetics, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.0012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455355PMC
April 2017

Advances in the management of patients with carcinoid syndrome.

Authors:
Matthew H Kulke

Clin Adv Hematol Oncol 2017 Apr;15(4):257-259

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
April 2017

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

J Clin Oncol 2017 Jan 28;35(1):14-23. Epub 2016 Oct 28.

Matthew H. Kulke, Dana-Farber Cancer Institute, Boston; Douglas Fleming, Ipsen Bioscience, Cambridge, MA; Dieter Hörsch, Zentralklinik Bad Berka, Bad Berka; Marianne Pavel, Charité-Universitätsmedizin, Berlin, Germany; Martyn E. Caplin, Royal Free Hospital, London; Juan W. Valle, The University of Manchester-The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Lowell B. Anthony, University of Kentucky, Lexington, KY; Emily Bergsland, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Pamela L. Kunz, Stanford University, Palo Alto, CA; Kjell Öberg and Staffan Welin, Uppsala University, Uppsala, Sweden; Richard R.P. Warner, Icahn School of Medicine at Mount Sinai, New York, NY; Catherine Lombard-Bohas, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Pablo Lapuerta, Phillip Banks, Shanna Jackson, Brian Zambrowicz, and Arthur T. Sands, Lexicon Pharmaceuticals, The Woodlands, TX; and Enrique Grande, Hospital Universitario Ramón y Cajal, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2780DOI Listing
January 2017

Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.

N Engl J Med 2017 01;376(2):125-135

From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895095PMC
January 2017

Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.

Pancreas 2016 11;45(10):1386-1393

From the *Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; †Department of Geriatric Gastroenterology, Chinese PLA General Hospital, Beijing, China; ‡Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA; §Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China; ∥IPSEN Bioscience Inc, Global Drug Discovery Department, Cambridge, MA; ¶IPSEN Innovation, Global Drug Discovery Department, Les Ulis, France; Departments of #Biostatistics, and **Epidemiology, Harvard T.H. Chan School of Public Health, ††Massachusetts General Hospital, ‡‡Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, §§Department of Radiology, Massachusetts General Hospital, and ∥∥Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/pancreasjournal/2016/11000/Asso
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067972PMC
http://dx.doi.org/10.1097/MPA.0000000000000700DOI Listing
November 2016

Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment.

Nucleic Acids Res 2016 Nov 18;44(19):e146. Epub 2016 Jul 18.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkw650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100565PMC
November 2016

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21.

Authors:
Mingfeng Zhang Zhaoming Wang Ofure Obazee Jinping Jia Erica J Childs Jason Hoskins Gisella Figlioli Evelina Mocci Irene Collins Charles C Chung Christopher Hautman Alan A Arslan Laura Beane-Freeman Paige M Bracci Julie Buring Eric J Duell Steven Gallinger Graham G Giles Gary E Goodman Phyllis J Goodman Aruna Kamineni Laurence N Kolonel Matthew H Kulke Núria Malats Sara H Olson Howard D Sesso Kala Visvanathan Emily White Wei Zheng Christian C Abnet Demetrius Albanes Gabriella Andreotti Lauren Brais H Bas Bueno-de-Mesquita Daniela Basso Sonja I Berndt Marie-Christine Boutron-Ruault Maarten F Bijlsma Hermann Brenner Laurie Burdette Daniele Campa Neil E Caporaso Gabriele Capurso Giulia Martina Cavestro Michelle Cotterchio Eithne Costello Joanne Elena Ugo Boggi J Michael Gaziano Maria Gazouli Edward L Giovannucci Michael Goggins Myron Gross Christopher A Haiman Manal Hassan Kathy J Helzlsouer Nan Hu David J Hunter Elzbieta Iskierka-Jazdzewska Mazda Jenab Rudolf Kaaks Timothy J Key Kay-Tee Khaw Eric A Klein Manolis Kogevinas Vittorio Krogh Juozas Kupcinskas Robert C Kurtz Maria T Landi Stefano Landi Loic Le Marchand Andrea Mambrini Satu Mannisto Roger L Milne Rachel E Neale Ann L Oberg Salvatore Panico Alpa V Patel Petra H M Peeters Ulrike Peters Raffaele Pezzilli Miquel Porta Mark Purdue J Ramón Quiros Elio Riboli Nathaniel Rothman Aldo Scarpa Ghislaine Scelo Xiao-Ou Shu Debra T Silverman Pavel Soucek Oliver Strobel Malin Sund Ewa Małecka-Panas Philip R Taylor Francesca Tavano Ruth C Travis Mark Thornquist Anne Tjønneland Geoffrey S Tobias Dimitrios Trichopoulos Yogesh Vashist Pavel Vodicka Jean Wactawski-Wende Nicolas Wentzensen Herbert Yu Kai Yu Anne Zeleniuch-Jacquotte Charles Kooperberg Harvey A Risch Eric J Jacobs Donghui Li Charles Fuchs Robert Hoover Patricia Hartge Stephen J Chanock Gloria M Petersen Rachael S Stolzenberg-Solomon Brian M Wolpin Peter Kraft Alison P Klein Federico Canzian Laufey T Amundadottir

Oncotarget 2016 Oct;7(41):66328-66343

Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340084PMC
October 2016

Emerging treatment options for carcinoid syndrome.

Authors:
Matthew H Kulke

Clin Adv Hematol Oncol 2016 Sep;14(9):666-7

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
September 2016

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.

BMC Cancer 2016 07 13;16:468. Epub 2016 Jul 13.

Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-0
Publisher Site
http://dx.doi.org/10.1186/s12885-016-2485-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944495PMC
July 2016

Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.

Neuroendocrinology 2015 29;101(4):274-88. Epub 2015 Apr 29.

Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000430816DOI Listing
April 2016

Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.

Surg Oncol Clin N Am 2016 Apr 19;25(2):423-37. Epub 2016 Feb 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 1220, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2015.11.009DOI Listing
April 2016

Somatostatin Analogues in Neuroendocrine Tumors.

Authors:
Matthew H Kulke

J Natl Compr Canc Netw 2016 Mar;14(3):241-2

View Article

Download full-text PDF

Source
March 2016

Neuroendocrine Tumors--Current and Future Clinical Advances.

Hematol Oncol Clin North Am 2016 Feb 20;30(1):xiii-xiv. Epub 2015 Oct 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2015.09.012DOI Listing
February 2016

Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.

Eur J Cancer 2016 Jan 4;53:163-70. Epub 2016 Jan 4.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.10.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724503PMC
January 2016

A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.

Annu Rev Med 2015 17;66:1-16. Epub 2014 Oct 17.

Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030; email: ,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-061813-012908DOI Listing
September 2015

Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.

Authors:
Matthew H Kulke

J Clin Oncol 2015 May 13;33(14):1534-8. Epub 2015 Apr 13.

Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0927DOI Listing
May 2015

Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.

J Clin Oncol 2015 Jan 17;33(1):29-35. Epub 2014 Nov 17.

Chen Yuan, Douglas A. Rubinson, Zhi Rong Qian, Shuji Ogino, Kimmie Ng, Megan J. Gorman, Lauren K. Brais, Tingting Li, Matthew H. Kulke, Charles S. Fuchs, and Brian M. Wolpin, Dana-Farber Cancer Institute; Chen Wu, Peter Kraft, Shuji Ogino, Meir J. Stampfer, Frank B. Hu, and Edward L. Giovannucci, Harvard School of Public Health; and Ying Bao, Shuji Ogino, Kimmie Ng, Thomas E. Clancy, Richard S. Swanson, Meir J. Stampfer, Frank B. Hu, Edward L. Giovannucci, Matthew H. Kulke, Charles S. Fuchs, and Brian M. Wolpin, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.5688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268250PMC
January 2015

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Lung Cancer 2014 Nov 27;86(2):241-6. Epub 2014 Aug 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293119PMC
November 2014

In reply.

Oncologist 2013 ;18(11):1240-1

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825312PMC
October 2014

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.

Endocr Relat Cancer 2014 Oct 10;21(5):705-14. Epub 2014 Jul 10.

Department of Medical OncologyDana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USAUniversity of Iowa Hospitals and ClinicsIowa City, Iowa, USAThe University of Texas M.D. Anderson Cancer CenterHouston, Texas, USAUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California, USALexicon Pharmaceuticals Inc.The Woodlands, Texas, USAH. Lee Moffitt Cancer CenterTampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-14-0173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295770PMC
October 2014

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.

Authors:
Brian M Wolpin Cosmeri Rizzato Peter Kraft Charles Kooperberg Gloria M Petersen Zhaoming Wang Alan A Arslan Laura Beane-Freeman Paige M Bracci Julie Buring Federico Canzian Eric J Duell Steven Gallinger Graham G Giles Gary E Goodman Phyllis J Goodman Eric J Jacobs Aruna Kamineni Alison P Klein Laurence N Kolonel Matthew H Kulke Donghui Li Núria Malats Sara H Olson Harvey A Risch Howard D Sesso Kala Visvanathan Emily White Wei Zheng Christian C Abnet Demetrius Albanes Gabriella Andreotti Melissa A Austin Richard Barfield Daniela Basso Sonja I Berndt Marie-Christine Boutron-Ruault Michelle Brotzman Markus W Büchler H Bas Bueno-de-Mesquita Peter Bugert Laurie Burdette Daniele Campa Neil E Caporaso Gabriele Capurso Charles Chung Michelle Cotterchio Eithne Costello Joanne Elena Niccola Funel J Michael Gaziano Nathalia A Giese Edward L Giovannucci Michael Goggins Megan J Gorman Myron Gross Christopher A Haiman Manal Hassan Kathy J Helzlsouer Brian E Henderson Elizabeth A Holly Nan Hu David J Hunter Federico Innocenti Mazda Jenab Rudolf Kaaks Timothy J Key Kay-Tee Khaw Eric A Klein Manolis Kogevinas Vittorio Krogh Juozas Kupcinskas Robert C Kurtz Andrea LaCroix Maria T Landi Stefano Landi Loic Le Marchand Andrea Mambrini Satu Mannisto Roger L Milne Yusuke Nakamura Ann L Oberg Kouros Owzar Alpa V Patel Petra H M Peeters Ulrike Peters Raffaele Pezzilli Ada Piepoli Miquel Porta Francisco X Real Elio Riboli Nathaniel Rothman Aldo Scarpa Xiao-Ou Shu Debra T Silverman Pavel Soucek Malin Sund Renata Talar-Wojnarowska Philip R Taylor George E Theodoropoulos Mark Thornquist Anne Tjønneland Geoffrey S Tobias Dimitrios Trichopoulos Pavel Vodicka Jean Wactawski-Wende Nicolas Wentzensen Chen Wu Herbert Yu Kai Yu Anne Zeleniuch-Jacquotte Robert Hoover Patricia Hartge Charles Fuchs Stephen J Chanock Rachael S Stolzenberg-Solomon Laufey T Amundadottir

Nat Genet 2014 Sep 3;46(9):994-1000. Epub 2014 Aug 3.

1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. [2].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.3052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191666PMC
September 2014

Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.

Oncologist 2014 Sep 5;19(9):930-6. Epub 2014 Aug 5.

Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA; Analysis Group, Inc., Boston, Massachusetts, USA; Department of Internal Medicine, University of South Florida, Tampa, Florida, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153451PMC
September 2014

Radiation recall associated with insulin growth factor 1R antibody.

Pract Radiat Oncol 2011 Jul-Sep;1(3):208-11. Epub 2011 Apr 30.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18798500100005
Publisher Site
http://dx.doi.org/10.1016/j.prro.2010.12.003DOI Listing
March 2014

Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.

Oncologist 2013 24;18(5):525-32. Epub 2013 Apr 24.

The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662843PMC
December 2013

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Cancer 2013 Sep 3;119(17):3212-8. Epub 2013 Jun 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308727PMC
September 2013

Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.

J Gastroenterol Hepatol 2013 Sep;28(9):1482-8

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.12286DOI Listing
September 2013

Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.

J Clin Oncol 2013 Sep 26;31(27):3418-25. Epub 2013 Aug 26.

Zhi Rong Qian, Monica Ter-Minassian, Jennifer A. Chan, Yu Imamura, Susanne M. Hooshmand, Aya Kuchiba, Teppei Morikawa, Lauren K. Brais, Anastassia Daskalova, Rachel Heafield, Charles S. Fuchs, Shuji Ogino, Matthew H. Kulke, Dana-Farber Cancer Institute and Harvard Medical School; Monica Ter-Minassian, Xihong Lin, David C. Christiani, Shuji Ogino, Harvard School of Public Health; David C. Christiani, Massachusetts General Hospital, Harvard Medical School; Charles S. Fuchs, Shuji Ogino, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/31/27/3418.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.46.6946
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.46.6946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770868PMC
September 2013

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

Cancer Chemother Pharmacol 2013 May 9;71(5):1241-6. Epub 2013 Mar 9.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-013-2118-9
Publisher Site
http://dx.doi.org/10.1007/s00280-013-2118-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029418PMC
May 2013

Are neuroendocrine tumors going mainstream?

Authors:
Matthew H Kulke

J Clin Oncol 2013 Feb 17;31(4):404-5. Epub 2012 Dec 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.3884DOI Listing
February 2013

Systemic therapy for advanced pancreatic neuroendocrine tumors.

Authors:
Matthew H Kulke

Semin Oncol 2013 Feb;40(1):75-83

Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2012.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029415PMC
February 2013

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.

Endocr Relat Cancer 2012 Oct 14;19(5):615-23. Epub 2012 Sep 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-11-0382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469068PMC
October 2012

Management of pancreatic neuroendocrine tumors.

Gastroenterol Clin North Am 2012 Mar;41(1):119-31

Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gtc.2011.12.003DOI Listing
March 2012

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

J Clin Endocrinol Metab 2011 Dec 12;96(12):3741-9. Epub 2011 Oct 12.

Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2011-0666DOI Listing
December 2011

Targeted therapy in advanced well-differentiated neuroendocrine tumors.

Oncologist 2011 23;16(3):286-95. Epub 2011 Feb 23.

Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2010-0313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228104PMC
August 2011

Genetic associations with sporadic neuroendocrine tumor risk.

Carcinogenesis 2011 Aug 23;32(8):1216-22. Epub 2011 May 23.

Environmental and Occupational Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgr095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149206PMC
August 2011

New treatment options for patients with advanced neuroendocrine tumors.

Curr Treat Options Oncol 2011 Jun;12(2):136-48

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-011-0148-2DOI Listing
June 2011

Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.

Carcinogenesis 2011 Apr 6;32(4):502-6. Epub 2011 Jan 6.

Environmental and Occupational Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, and Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/carcin/article-lookup/doi/10.1093/c
Publisher Site
http://dx.doi.org/10.1093/carcin/bgq287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066416PMC
April 2011

Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.

Neoplasia 2011 Apr;13(4):386-92

Environmental and Occupational Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071087PMC
http://dx.doi.org/10.1593/neo.101722DOI Listing
April 2011

Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.

Cancer Chemother Pharmacol 2010 Oct 4;66(5):961-8. Epub 2010 Feb 4.

Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1248-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755014PMC
October 2010

A Large-scale genetic association study of esophageal adenocarcinoma risk.

Carcinogenesis 2010 Jul 7;31(7):1259-63. Epub 2010 May 7.

Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgq092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893800PMC
July 2010

Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Gastrointest Cancer Res 2009 Sep;3(5 Supplement 2):S62-6

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791386PMC
September 2009